PeterMVoorheesMD

Hematologic Oncology

Professor of Medicine, Department of Hematologic Oncology and Blood Disorders, Division of Plasma Cell Disorders, Levine Cancer Institute, Atrium Health

Join to view full profile

Dr. Voorhees is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Voorhees' full profile

Already have an account?

Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204
Phone+1 980-442-2000

Fax+1 980-442-5241

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1997 - 2001
University of Michigan Medical SchoolClass of 1997

Certifications & Licensure

NC State Medical License 2001 - 2025
WI State Medical License 1998 - 2001
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Top MD Consumers Checkbook

Clinical Trials

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy Start of enrollment: 2008 Aug 01
Completed
Phase 2
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2008 Oct 01
Terminated
Phase 1
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 Apr 01
Withdrawn
Phase 2
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma Start of enrollment: 2012 Jul 12
Completed
Phase 1
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma Start of enrollment: 2012 Mar 01
Unknown status
Phase 1, Phase 2
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Start of enrollment: 2009 Apr 21
Terminated
Phase 2
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2014 Feb 01
Active, not recruiting
Phase 1, Phase 2
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML Start of enrollment: 2021 Jul 12
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS.
Carl Ola Landgren, Ajai Chari, Yael C Cohen, Andrew Spencer, Peter M Voorhees
Blood. 2024-12-09
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma.
Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry A Paul
Blood Advances. 2024-11-22
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
Future Oncology. 2024-10-25

Journal Articles

International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood

Abstracts/Posters

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Result...
Peter M. Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab ﴾Dara﴿, Bortezomib ﴾V﴿, Lenalidomide ﴾R﴿, and De...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

International Myeloma Foundation Medical Student Scholars for Health Equity in Myeloma Present Posters at the 2024 NMA Annual Convention & Scientific AssemblyAugust 15th, 2024
ATLAS Trial: Risk-Adapted Triplet Maintenance Therapy May Benefit Some Patients with Multiple MyelomaAugust 1st, 2022
Frontline Therapy for Multiple MyelomaMay 3rd, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member